Parkside Financial Bank & Trust Bio Xcel Therapeutics, Inc. Transaction History
Parkside Financial Bank & Trust
- $742 Million
- Q4 2024
A detailed history of Parkside Financial Bank & Trust transactions in Bio Xcel Therapeutics, Inc. stock. As of the latest transaction made, Parkside Financial Bank & Trust holds 1,800 shares of BTAI stock, worth $3,888. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,800
Previous 1,800
-0.0%
Holding current value
$3,888
Previous $1,000
100.0%
% of portfolio
0.0%
Previous 0.0%
Shares
1 transactions
Others Institutions Holding BTAI
# of Institutions
52Shares Held
8.63MCall Options Held
34.5KPut Options Held
59.4K-
Armistice Capital, LLC New York, NY4.32MShares$9.32 Million0.02% of portfolio
-
Ubs Group Ag1.28MShares$2.76 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.19MShares$2.56 Million0.0% of portfolio
-
Black Rock Inc. New York, NY441KShares$951,8790.0% of portfolio
-
Geode Capital Management, LLC Boston, MA312KShares$673,8440.0% of portfolio
About BioXcel Therapeutics, Inc.
- Ticker BTAI
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 28,022,500
- Market Cap $60.5M
- Description
- BioXcel Therapeutics, Inc. is a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and prop...